2014
The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: A double-blind, randomized, placebo-controlled trial
Tek C, Palmese LB, Krystal AD, Srihari VH, DeGeorge PC, Reutenauer EL, Guloksuz S. The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: A double-blind, randomized, placebo-controlled trial. Schizophrenia Research 2014, 160: 180-185. PMID: 25454802, PMCID: PMC5589464, DOI: 10.1016/j.schres.2014.10.002.Peer-Reviewed Original ResearchMeSH KeywordsAzabicyclo CompoundsCognitionDouble-Blind MethodEszopicloneFemaleHumansHypnotics and SedativesMaleMedical RecordsMiddle AgedPatient DropoutsPiperazinesPsychotic DisordersQuality of LifeSchizophreniaSchizophrenic PsychologySingle-Blind MethodSleepSleep Initiation and Maintenance DisordersTreatment OutcomeConceptsInsomnia Severity IndexSingle-blind placebo phasePlacebo phaseOutcome measuresPsychiatric symptomsPlacebo-controlled trialDouble-blind placeboSecondary outcome measuresPrimary outcome measureEffects of eszopicloneBetween-group differencesTreatment of insomniaQuality of lifeDiscontinuation ratesMATRICS Consensus Cognitive BatteryStable outpatientsConsensus Cognitive BatterySchizoaffective disorderCognitive impairmentSleep diaryPatientsInsomniaScore changeEszopiclonePlacebo
2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight loss